Dexcom is facing scrutiny and class-action lawsuits over alleged safety and accuracy issues with its G7 monitor.

Dexcom has issued a Class I recall for its G6 Android app due to crashes that could cause users to miss critical glucose ...

If you have suffered a loss on your DexCom, Inc. ("DexCom" or the "Company") (NASDAQ:DCXM) investment, contact Thomas W. Elrod of Kirby McInerney LLP by email at [email protected], or fill out ...

Stifel projected that the 15-day sensor could enhance DexCom’s gross margin in 2026, potentially contributing to year-over-year EBITDA margin expansion. The firm acknowledged certain risks, including ...

Thank you, operator, and welcome to DexCom's Third Quarter 2025 Earnings Call. Our agenda begins with Jake Leach, DexCom's President and Interim CEO, who will summarize our recent highlights and ...

Investing.com - Stifel resumed coverage of DexCom (NASDAQ:DXCM) with a Buy rating and set a price target of $85.00, according to a research note published Monday. The company, currently trading at $68 ...

Describes the nature of a clinical study. Types include: Observational study — observes people and measures outcomes without affecting results. Interventional study (clinical trial) — studies new ...